Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G., Ebetino F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite // Bone. 2006. Vol. 38. Р. 617–627.
Oliver D., Connelly J.B., Victor C.R., Shaw F.E., Whitehead A., Genc Y. et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007, 334: 82.
Pazians M., Blumentals W.A., Miller P.D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker // Osteoporosis International. 2008. Vol. 19. Р. 773–779.
Peterlik M., Cross H.S. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology // Eur. J. Clin. Nutr. 2009.
Pilz S., Dobnig H., Fischer J.E., Wellnitz B., Seelhorst U., Boehm B.O., Marz W. (2008) Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 39:2611–2613.
Pilz S., Marz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., Boehm B.O., Dobnig H. (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93: 3927–3935.
Pilz S., Tomaschitz A., Drechsler C., Dekker J.M., Marz W. Vitamin D deficiency and myocardial diseases. //Mol Nutr Food, 2010, Res 54:1103–1113.
Pilz S., Tomaschitz A., Ritz E., Pieber T.R. (2009) Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 6: 621–630.
Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92: 2017–2029.
Recker R., Ensrud K., Diem S. et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women // J. Bone Miner. Res. 2004; 19:45.
Recker О.Р., Delmas P.D., Halse J. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008 Jan; 23(1): 6–16.
Recker О.Р., Weinstein R.S., Chesnut C.H. 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004 Mar. 15(3): 231–7.
Reid I.R., Schooler B.A., Hannan S.F., Ibbertson H.K. (1986) The acute biochemical effects of four proprietary calcium preparations. Aust N Z J Med 16: 193–197.
Rodan G., Reszka A., Golub E., Rizzoli R. Bone safety of long-term bisphosphonate treatment // Curr. Med. Res. Opin. 2004; 20(8): 1291–1300.
Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of actions of bisphosphonates: similarities and differences and their potential influence on clinical efficacy // Osteoporosis International. 2008. Vol. 19.Р. 733–759.
Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 83: 754–759.
Shaheen N.J. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1790–1791.
Simon J.A., Lewiecki E.M., Smith M.E. et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, cross-over study // Clin. Ther. 2002. V. 24. P. 1871–1886.
Siris E.S., Oster M.W., Bilezikian J.P. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1791.
